Nautilus Biotechnology, Inc. (NAUT)
NasdaqCM
Price as at 30 Sept 2026, 21:37 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Nautilus Biotechnology, Inc. trades at $1.42. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$3.55M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$1.29M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$496.6K · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$352.9K · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$127.0K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own NAUT?
5 of the institutions we track reported a position in NAUT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its NAUT data?
Fundamentals for NAUT come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:37 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NAUT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.